Lilly, Aifa approves mirikizumab: first drug of a new class reimbursed for the treatment of ulcerative colitis

The pharmaceutical company Lilly organized the press conference “Ulcerative colitis: from patient needs to new perspectives”, a chronic intestinal disease that affects approximately 150,000 people in Italy, with over 4,000 new diagnoses per year, during which the importance of mirikizumab was highlighted, the first interleukin-23p19 antagonist for the treatment of moderate to severe active ulcerative colitis in adult patients, whose reimbursement has been approved by the Italian Medicines Agency.